← Back to Screener
Lyra Therapeutics, Inc. Common Stock (LYRA)
Price$0.66
Favorite Metrics
Price vs S&P 500 (26W)-98.26%
Price vs S&P 500 (4W)54.71%
Market Capitalization$1.43M
All Metrics
Book Value / Share (Quarterly)$1.00
P/TBV (Annual)1.87x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)74.24%
Cash Flow / Share (Quarterly)$-20.74
Price vs S&P 500 (YTD)-78.01%
Net Profit Margin (TTM)-5491.17%
EPS (TTM)$-23.78
10-Day Avg Trading Volume0.01M
EPS Excl Extra (TTM)$-23.78
Revenue Growth (5Y)4.35%
EPS (Annual)$-71.75
ROI (Annual)-805.89%
Net Profit Margin (5Y Avg)-5933.70%
Cash / Share (Quarterly)$13.41
Revenue Growth QoQ (YoY)-87.18%
ROA (Last FY)-140.83%
Revenue Growth TTM (YoY)-59.21%
EBITD / Share (TTM)$-23.56
ROE (5Y Avg)-220.19%
Operating Margin (TTM)-5885.33%
Cash Flow / Share (Annual)$-55.22
P/B Ratio0.88x
P/B Ratio (Quarterly)8.98x
Net Income / Employee (Annual)$-3
EV / Revenue (TTM)-34.38x
ROA (TTM)-60.19%
EPS Incl Extra (Annual)$-71.75
Current Ratio (Annual)3.41x
Quick Ratio (Quarterly)2.33x
3-Month Avg Trading Volume0.08M
52-Week Price Return-82.51%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$1.70
P/S Ratio (Annual)0.93x
Asset Turnover (Annual)0.02x
52-Week High$37.50
Operating Margin (5Y Avg)-6071.24%
EPS Excl Extra (Annual)$-71.75
CapEx CAGR (5Y)61.93%
26-Week Price Return-89.51%
Quick Ratio (Annual)3.21x
13-Week Price Return-57.43%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)2.43x
Enterprise Value$-20.627
Revenue / Share Growth (5Y)63.77%
Asset Turnover (TTM)0.01x
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-6088.40%
Cash / Share (Annual)$30.97
3-Month Return Std Dev186.78%
Net Income / Employee (TTM)$-1
ROE (Last FY)-805.89%
EPS Basic Excl Extra (Annual)$-71.75
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-23.78
ROI (TTM)-411.98%
P/S Ratio (TTM)2.38x
Pretax Margin (5Y Avg)-5932.29%
Revenue / Share (Annual)$1.18
Tangible BV / Share (Annual)$2.54
Price vs S&P 500 (52W)-117.60%
Year-to-Date Return-73.88%
5-Day Price Return23.78%
EPS Normalized (Annual)$-71.75
ROA (5Y Avg)-68.34%
Net Profit Margin (Annual)-6090.94%
Month-to-Date Return63.84%
Cash Flow / Share (TTM)$-1.41
EBITD / Share (Annual)$-73.62
Operating Margin (Annual)-6280.83%
ROI (5Y Avg)-220.19%
EPS Basic Excl Extra (TTM)$-23.78
P/TBV (Quarterly)1.80x
P/B Ratio (Annual)1.17x
Pretax Margin (TTM)-5488.67%
Book Value / Share (Annual)$8.85
Price vs S&P 500 (13W)-60.29%
Beta0.72x
Revenue / Share (TTM)$0.34
ROE (TTM)-411.98%
52-Week Low$0.31
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
2.44
2.17
2.17
2.17
Industry Peers — Surgical & Medical Instruments(108)
| Symbol | P/S Ratio (TTM) | Revenue Growth (5Y) | Gross Margin (TTM) | Operating Margin (TTM) | Price |
|---|---|---|---|---|---|
LYRALyra Therapeutics, Inc. Common Stock | 2.38x | 4.35% | — | -5885.33% | $0.66 |
SYKStryker Corporation | 5.24x | 11.84% | 64.57% | 19.43% | $343.32 |
BSXBoston Scientific Corp. | 4.75x | 15.16% | 69.01% | 18.00% | $64.23 |
MMM3M Company | 3.26x | -4.97% | 39.92% | 18.55% | $154.55 |
MDLNMedline Inc. Class A common stock | 2.20x | — | 26.44% | 7.78% | $47.64 |
BDXBecton, Dickinson and Co. | 2.06x | 6.32% | 46.42% | 12.15% | $158.54 |
RMDResMed Inc. | 6.16x | 11.72% | 60.85% | 33.70% | $228.12 |
DXCMDexCom, Inc. | 5.28x | 19.33% | 62.09% | 19.56% | $63.98 |
WSTWest Pharmaceutical Services, Inc. | 6.29x | 7.44% | 35.91% | 19.03% | $273.73 |
PODDInsulet Corporation | 5.30x | 24.53% | 71.63% | 12.92% | $203.73 |
PENPenumbra, Inc. | 9.30x | 20.16% | 67.14% | 13.48% | $332.13 |
About
Lyra Therapeutics is a clinical-stage biopharmaceutical company developing innovative drug delivery solutions for ear, nose, and throat (ENT) diseases. The company's lead product candidates, LYR-210 and LYR-220, are bioabsorbable polymeric matrices administered in brief, non-invasive in-office procedures to deliver continuous therapy directly to the sinonasal passages for chronic rhinosinusitis. This localized delivery approach aims to provide therapeutic benefits while minimizing systemic exposure.